Agape ATP CorpATPC

Agape ATP Corp-known to its filings as Agape ATP Corporation and to its customers as Agape Superior Living-is a micro-cap wellness outfit whose public documents describe a ‘digital wellness platform’ and two product lines: ATP Zeta health programs and E.A.T.S. products, yet the latest 10-Q shows quarterly revenues of only $273,658 against a $340,906 net loss. The company’s cash balance was $220,779 at 31 March 2026, while operating cash flow was negative $394,770, a rate that would exhaust the coffers in little over six weeks if the burn continues unchecked. (source: SEC EDGAR 10-Q, https://www.sec.gov/Archives/edgar/data/1713210/000149315226023388/form10-q.htm)

Agape ATP Corp’s product pages promise ‘ionized and high Zeta potential cell foods’ that are ‘entirely absorbed by our body in minutes,’ but the same pages do not disclose the company’s single largest customer contract is a mere $3,274 due within twelve months, nor that quarterly revenues from health and wellness services fell to $38,330 from $42,700 a year earlier. The tension between the aspirational product narrative and the filed financial reality is wider than the company’s $24,788 of inventory. (source: SEC EDGAR S-1/A, https://www.sec.gov/Archives/edgar/data/1713210/000149315226033881/forms-1a.htm; AGAPE SUPERIOR LIVING, https://www.agapeatp.com/index.php/en/products/e-a-t-s; AGAPE SUPERIOR LIVING, https://www.agapeatp.com/index.php/en/products/atp-zeta)

The company’s S-1/A filing of 20 July 2026 sets out plans for a ‘comprehensive digital wellness platform that integrates e-commerce,’ yet the same document reveals that the firm’s total revenue for the quarter ended 31 March 2026 was $273,658, with operating income of negative $677,372 and diluted loss per share of $0.33 on 1.0 million diluted shares. Assets stood at $24.9 million against liabilities of $2.8 million, leaving shareholders’ equity at $22.1 million. Capital expenditure was a trivial $649 in the prior year, and inventories declined by $749 in the latest quarter. (source: SEC EDGAR 10-Q, https://www.sec.gov/Archives/edgar/data/1713210/000149315226023388/form10-q.htm)

For readers who rely on market mechanisms, the company’s SEC filings do not provide a public price history or chart route; the TradingView symbol ‘ATPC’ is not referenced in the evidence pack and therefore cannot be used to infer price levels or liquidity. Prospective participants should treat any charting claims as unverified until the issuer or an exchange publishes a trade-price feed or depth-of-market data. (source: SEC EDGAR filing index, https://www.sec.gov/edgar/browse/?CIK=1713210)

What changed in the last reporting cycle is a modest decline in service revenues and a continued cash burn at a rate that outpaces the company’s cash balance. What remains unproven is whether the promised digital wellness platform can materially expand revenues above the $300k-per-quarter level, given that the company’s largest disclosed contract is only $3,274 and its product pages highlight ionized cell foods rather than documented revenue growth. Evidence that would deepen the file would include audited annual revenues above $2m, positive operating cash flow, and a governance disclosure of insider share ownership or dilution history beyond the generic S-1 text. (source: SEC EDGAR 10-Q, https://www.sec.gov/Archives/edgar/data/1713210/000149315226023388/form10-q.htm; SEC EDGAR S-1, https://www.sec.gov/Archives/edgar/data/1713210/000149315226027669/forms-1.htm)